[Clinical implications of bisphosphonate for bone metastases of prostate cancer].
作者信息
Kitagawa Yasuhide, Konaka Hiroyuki, Mizokami Atsushi, Namiki Mikio
机构信息
Department of Urology, School of Medicine, Kanazawa University.
出版信息
Nihon Rinsho. 2007 Nov 28;65 Suppl 9:356-9.
PMID:18161131
Abstract
摘要
相似文献
1
[Clinical implications of bisphosphonate for bone metastases of prostate cancer].
Nihon Rinsho. 2007 Nov 28;65 Suppl 9:356-9.
2
[Clinical study of bisphosphonates for bone metastasis in breast cancer].
Nihon Rinsho. 2007 Nov 28;65 Suppl 9:352-5.
3
[Bisphosphonate treatment against breast cancer with bone metastases].
Nihon Rinsho. 2007 Jun 28;65 Suppl 6:575-81.
4
Bisphosphonates effective in preventing bone complications associated with androgen deprivation therapy.
J Support Oncol. 2006 Feb;4(2):99-100.
5
Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Expert Rev Anticancer Ther. 2009 Sep;9(9):1211-8. doi: 10.1586/era.09.95.
6
Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
Urol Oncol. 2006 Jan-Feb;24(1):4-12. doi: 10.1016/j.urolonc.2005.06.020.
7
Natural history and treatment of bone complications in prostate cancer.
Eur Urol. 2006 Mar;49(3):429-40. doi: 10.1016/j.eururo.2005.12.045. Epub 2006 Jan 6.
8
Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies.
Expert Rev Anticancer Ther. 2010 Dec;10(12):1991-2002. doi: 10.1586/era.10.191.
9
Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
Actas Urol Esp. 2013 May;37(5):292-304. doi: 10.1016/j.acuro.2012.09.001. Epub 2012 Dec 13.
10
Pharmacotherapy of bone metastases in breast cancer patients.
Expert Opin Pharmacother. 2008 Apr;9(6):937-45. doi: 10.1517/14656566.9.6.937.
Zotero 插件